Skip to main content
Customer Milestone , News & Announcements , Nottingham, UK

Quotient Sciences and Nanomerics dose first volunteers in the OC134 SUNLIGHT trial

Analysis of Insulin Analogues at Quotient Sciences

Following approval in November from the UK Medicinal and Healthcare Products Regulatory Agency (MHRA), Nanomerics Ltd., a private speciality pharmaceutical company, and Quotient Sciences have commenced dosing the first volunteers for the Phase I trial of OC134.

OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment, does not currently exist.

The clinical testing of Nanomerics’ eye drop assets is being done by Quotient Sciences - Nottingham, UK.

Dr Nand Singh, Medical Director at Quotiexnt Sciences commented, “We are excited to begin clinical testing at our Nottingham, UK clinic for Nanomerics’ OC134 Phase 1 Sunlight trial. This marks an important step forward in developing advanced treatments for moderate to severe conjunctivitis.”  

Continue reading the announcement from Nanomerics 

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, commercial manufacturing, Dr. Helen Baker, Dr. Richard Castledine Dr. Helen Baker and Dr. Richard Castledine contribute to Pharmaceutical Technology's 'Poor API Quality Threatens a Healthy Supply' By: Dr. Helen Baker and Dr. Richard Castledine
Read More
News & Announcements, Articles & Publications, Thierry Van Nieuwenhove Thierry Van Nieuwenhove on the Future of CDMO Partnerships By: Thierry Van Nieuwenhove
Read More
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Read More
Get in touch
Humanity can't afford to wait, so neither can we.